Overview
GHK-Cu denotes the complex of the tripeptide glycyl-L-histidyl-L-lysine (GHK) with copper(II) ions. The tripeptide was described in 1973 as a constituent of human serum and binds copper with high affinity. This entry covers structure, origin and analytical aspects only.
Scientific background
Origin
The tripeptide GHK was isolated from human serum and described in 1973 by Pickart and Thaler. It subsequently emerged that GHK binds copper(II) ions strongly. In nomenclature databases the copper complex is also listed under the name ‘prezatide copper’.
Structure of the peptide
GHK consists of three amino acids: glycine at the N-terminus, histidine in the middle and lysine at the C-terminus. The free tripeptide has the molecular formula C₁₄H₂₄N₆O₄ and an average molar mass of about 340.4 g/mol. In addition to the N-terminal amino group, it carries two further protonatable groups – the imidazole ring of histidine and the ε-amino group of lysine – as well as the C-terminal carboxyl group.
The copper complex
According to the usual description, Cu(II) coordinates to three nitrogen atoms: the N-terminal amino group of glycine, the deprotonated amide nitrogen of the Gly-His peptide bond and a nitrogen of the imidazole ring. Depending on conditions, the remaining coordination sites are occupied by water, carboxylate groups or neighbouring molecules. Aqueous solutions of the complex are typically blue.
Molecular data
The CAS number 89030-95-5 is registered for the 1:1 copper complex (PubChem). Molecular formula and molar mass, however, are given differently in databases and data sheets, depending on the stoichiometry, charge and protonation state and the counterions – acetate, for example – assumed. This entry therefore gives no general values for the complex; the information for the specific batch is authoritative.
Analytical characterisation
In analysis it should be borne in mind that metal complexes can partly dissociate under the acidic conditions of reversed-phase HPLC. Because the tripeptide is very polar, it also elutes early in reversed-phase HPLC, which influences the choice of column and gradient. The identity of the peptide component can be confirmed by mass spectrometry; copper content is determined by elemental methods such as ICP-OES or ICP-MS. The salt form should be stated on the certificate of analysis.
Molecular data
- Sequence
- Gly-His-Lys
- CAS number
- 89030-95-5
State of research
The literature on GHK and its copper complex comprises studies of its coordination chemistry and predominantly preclinical work, that is, cell culture and animal studies. An editorially reviewed summary of the state of research with verified sources is in preparation. This entry deliberately makes no statements about effects.
Sources
The sources for this entry are currently being verified by the editorial team and will appear once verified.
Safety and research notes
- For research and analytical purposes only. Not for use in humans or animals.
- The toxicological properties have not been fully investigated; handle the substance with appropriate caution.
- Wear a lab coat, safety glasses and gloves; open powders only in a weighing enclosure or fume hood and do not inhale dust.
- Collect copper-containing residues and solutions separately and do not pour them down the drain; follow the safety data sheet for the batch in question.